Roche Holding AG (OTCMKTS:RHHBY) Receives $40.00 Consensus Target Price from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has earned an average rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $40.00.

Several equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised Roche from a “sell” rating to a “hold” rating in a report on Friday, May 17th. Argus reaffirmed a “hold” rating on shares of Roche in a report on Monday, March 4th.

Institutional Investors Weigh In On Roche

Institutional investors have recently modified their holdings of the company. AlphaMark Advisors LLC purchased a new position in Roche during the 1st quarter valued at about $34,000. Wetzel Investment Advisors Inc. purchased a new stake in Roche in the 4th quarter valued at approximately $53,000. Operose Advisors LLC acquired a new stake in Roche during the 3rd quarter valued at $59,000. First Horizon Advisors Inc. increased its position in Roche by 19.8% during the fourth quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock worth $75,000 after buying an additional 342 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of Roche in the fourth quarter worth $146,000.

Roche Stock Down 0.6 %

RHHBY opened at $31.60 on Monday. The business has a 50 day moving average price of $31.02 and a two-hundred day moving average price of $33.25. Roche has a 52 week low of $29.20 and a 52 week high of $40.48. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.